The Influenza Virus Polymerase Complex: An Update on Its Structure, Functions, and Significance for Antiviral Drug Design

Medicinal Research Reviews

Volumn 36, Issue 6, 2016, Pages 1127-1173

  Stevaert, Annelies ^a   Naesens, Lieve ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

antiviral; cap snatching; influenza virus; nucleoside; polymerase

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 FLUORO 4 IODOANILINO) 1,6 DIHYDRO N (2 HYDROXYETHOXY) 1,5 DIMETHYL 6 OXONICOTINAMIDE; 5 ETHYNYL 4 IMIDAZOLECARBOXAMIDE 1 RIBOSIDE; ACETYLSALICYLIC ACID; AMITIVIR; ANTIVIRUS AGENT; AZACITIDINE; BENZBROMARONE; BENZOFURAN DERIVATIVE; CARBODINE; DEZAGUANINE; DICLAZURIL; FAVIPIRAVIR; FLUOROURACIL; GELDANAMYCIN; METHYLPHOSPHONOTHIOIC ACID S (2 DIISOPROPYLAMINOETHYL) O ETHYL ESTER; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NAPROXEN; PIRAZOFURIN; POLYMERASE BASIC PROTEIN 1; POLYMERASE BASIC PROTEIN 2; RADAVIRSEN; RIBAVIRIN; SELENAZOFURIN; SELUMETINIB; TARIBAVIRIN; UNCLASSIFIED DRUG; VERDINEXOR; VIRAL PROTEIN; VIRUS NUCLEOPROTEIN; VIRUS RNA; PB2 PROTEIN, INFLUENZAVIRUS A; RNA DIRECTED RNA POLYMERASE;

AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CRYSTAL STRUCTURE; DRUG DESIGN; ENZYME ACTIVITY; HOST CELL; HUMAN; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VIRUS; NONHUMAN; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; RNA BINDING; RNA SYNTHESIS; VIRUS REPLICATION; VIRUS TRANSCRIPTION; ANIMAL; CHEMISTRY; ENZYMOLOGY; INFLUENZA A VIRUS (H1N1); METABOLISM; MOLECULAR MODEL;

ANIMALS; ANTIVIRAL AGENTS; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA B VIRUS; MODELS, MOLECULAR; RNA REPLICASE; VIRAL NONSTRUCTURAL PROTEINS; VIRAL PROTEINS;

EID: 84991769513     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21401     Document Type: Review

References (265)

1. Krammer F, Palese P. Advances in the development of influenza virus vaccines. Nat Rev Drug Discov 2015;14:167–182.
2. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: An ongoing controversy. Lancet Infect Dis 2007;7:658–666.
3. Madhi SA, Cutland CL, Kuwanda L, Weinberg A, Hugo A, Jones S, Adrian PV, van Niekerk N, Treurnicht F, Ortiz JR, Venter M, Violari A, Neuzil KM, Simões EA, Klugman KP, Nunes MC. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med 2014;371:918–931.
4. Gu RX, Liu LA, Wei DQ. Structural and energetic analysis of drug inhibition of the influenza A M2 proton channel. Trends Pharmacol Sci 2013;34:571–580.
5. Pielak RM, Oxenoid K, Chou JJ. Structural investigation of rimantadine inhibition of the AM2-BM2 chimera channel of influenza viruses. Structure 2011;19:1655–1663.
6. Jefferson T, Demicheli V, Di Pietrantonj C, Rivetti D. Amantadine and rimantadine for influenza A in adults. Cochrane Database Syst Rev 2006:CD001169. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001169.pub3/pdf/abstract
7. Deyde VM, Xu X, Bright RA, Shaw M, Smith CB, Zhang Y, Shu Y, Gubareva LV, Cox NJ, Klimov AI. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 2007;196:249–257.
8. Moscona A. Global transmission of oseltamivir-resistant influenza. N Engl J Med 2009;360:953–956.
9. Thorlund K, Awad T, Boivin G, Thabane L. Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis 2011;11:134.
10. Samson M, Pizzorno A, Abed Y, Boivin G. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res 2013;98:174–185.
11. McKimm-Breschkin JL, Fry AM. Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses. Antiviral Res 2016;129:21–38.
12. Das K, Aramini JM, Ma LC, Krug RM, Arnold E. Structures of influenza A proteins and insights into antiviral drug targets. Nat Struct Mol Biol 2010;17:530–538.
13. Fodor E. The RNA polymerase of influenza A virus: Mechanisms of viral transcription and replication. Acta Virol 2013;57:113–122.
14. Eisfeld AJ, Neumann G, Kawaoka Y. At the centre: Influenza A virus ribonucleoproteins. Nat Rev Microbiol 2015;13:28–41.
15. Ortín J, Martín-Benito J. The RNA synthesis machinery of negative-stranded RNA viruses. Virology 2015;479-480:532–544.
16. Reguera J, Gerlach P, Cusack S. Towards a structural understanding of RNA synthesis by negative strand RNA viral polymerases. Curr Opin Struct Biol 2016;36:75–84.
17. Moeller A, Kirchdoerfer RN, Potter CS, Carragher B, Wilson IA. Organization of the influenza virus replication machinery. Science 2012;338:1631–1634.
18. Arranz R, Coloma R, Chichón FJ, Conesa JJ, Carrascosa JL, Valpuesta JM, Ortín J, Martín-Benito J. The structure of native influenza virion ribonucleoproteins. Science 2012;338:1634–1637.
19. Bouloy M, Plotch SJ, Krug RM. Globin mRNAs are primers for the transcription of influenza viral RNA in vitro. Proc Natl Acad Sci USA 1978;75:4886–4890.
20. 7GpppXm)-dependent influenza virion endonuclease cleaves capped RNAs to generate the primers that initiate viral RNA transcription. Cell 1981;23:847–858.
21. Robertson JS, Schubert M, Lazzarini RA. Polyadenylation sites for influenza virus mRNA. J Virol 1981;38:157–163.
22. Poon LL, Pritlove DC, Fodor E, Brownlee GG. Direct evidence that the poly(A) tail of influenza A virus mRNA is synthesized by reiterative copying of a U track in the virion RNA template. J Virol 1999;73:3473–3476.
23. Pflug A, Guilligay D, Reich S, Cusack S. Structure of influenza A polymerase bound to the viral RNA promoter. Nature 2014;516:355–360.
24. Reich S, Guilligay D, Pflug A, Malet H, Berger I, Crépin T, Hart D, Lunardi T, Nanao M, Ruigrok RW, Cusack S. Structural insight into cap-snatching and RNA synthesis by influenza polymerase. Nature 2014;516:361–366.
25. Portela A, Digard P. The influenza virus nucleoprotein: A multifunctional RNA-binding protein pivotal to virus replication. J Gen Virol 2002;83:723–734.
26. Boivin S, Cusack S, Ruigrok RW, Hart DJ. Influenza A virus polymerase: Structural insights into replication and host adaptation mechanisms. J Biol Chem 2010;285:28411–28417.
27. Gabriel G, Fodor E. Molecular determinants of pathogenicity in the polymerase complex. Curr Top Microbiol Immunol 2014;385:35–60.
28. Rodriguez-Frandsen A, Alfonso R, Nieto A. Influenza virus polymerase: Functions on host range, inhibition of cellular response to infection and pathogenicity. Virus Res 2015;209:23–38.
29. Long JS, Giotis ES, Moncorgé O, Frise R, Mistry B, James J, Morisson M, Iqbal M, Vignal A, Skinner MA, Barclay WS. Species difference in ANP32A underlies influenza A virus polymerase host restriction. Nature 2016;529:101–104.
30. Ulmanen I, Broni BA, Krug RM. Role of two of the influenza virus core P proteins in recognizing cap 1 structures (m7GpppNm) on RNAs and in initiating viral RNA transcription. Proc Natl Acad Sci USA 1981;78:7355–7359.
31. Blaas D, Patzelt E, Kuechler E. Identification of the cap binding protein of influenza virus. Nucleic Acids Res 1982;10:4803–4812.
32. Guilligay D, Tarendeau F, Resa-Infante P, Coloma R, Crépin T, Sehr P, Lewis J, Ruigrok RW, Ortín J, Hart DJ, Cusack S. The structural basis for cap binding by influenza virus polymerase subunit PB2. Nat Struct Mol Biol 2008;15:500–506.
33. Xie L, Wartchow C, Shia S, Uehara K, Steffek M, Warne R, Sutton J, Muiru GT, Leonard VH, Bussiere DE, Ma X. Molecular basis of mRNA cap recognition by influenza B polymerase PB2 subunit. J Biol Chem 2016;291:363–370.
34. Liu Y, Yang Y, Fan J, He R, Luo M, Zheng X. The crystal structure of the PB2 cap-binding domain of influenza B virus reveals a novel cap recognition mechanism. J Biol Chem 2015;290:9141–9149.
35. Wakai C, Iwama M, Mizumoto K, Nagata K. Recognition of cap structure by influenza B virus RNA polymerase is less dependent on the methyl residue than recognition by influenza A virus polymerase. J Virol 2011;85:7504–7512.
36. Pautus S, Sehr P, Lewis J, Fortuné A, Wolkerstorfer A, Szolar O, Guilligay D, Lunardi T, Décout JL, Cusack S. New 7-methylguanine derivatives targeting the influenza polymerase PB2 cap-binding domain. J Med Chem 2013;56:8915–8930.
37. Clark MP, Ledeboer MW, Davies I, Byrn RA, Jones SM, Perola E, Tsai A, Jacobs M, Nti-Addae K, Bandarage UK, Boyd MJ, Bethiel RS, Court JJ, Deng H, Duffy JP, Dorsch WA, Farmer LJ, Gao H, Gu W, Jackson K, Jacobs DH, Kennedy JM, Ledford B, Liang J, Maltais F, Murcko M, Wang T, Wannamaker MW, Bennett HB, Leeman JR, McNeil C, Taylor WP, Memmott C, Jiang M, Rijnbrand R, Bral C, Germann U, Nezami A, Zhang Y, Salituro FG, Bennani YL, Charifson PS. Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. J Med Chem 2014;57:6668–6678.
38. Roch FF, Hinterkörner G, Menke J, Tang GQ, Cusack S, Butzendobler B, Buschmann H, Datta K, Wolkerstorfer A. An RNA hybridization assay for screening influenza A virus polymerase inhibitors using the entire ribonucleoprotein complex. Assay Drug Dev Technol 2015;13:488–506.
39. Hooker L, Sully R, Handa B, Ono N, Koyano H, Klumpp K. Quantitative analysis of influenza virus RNP interaction with RNA cap structures and comparison to human cap binding protein eIF4E. Biochemistry 2003;42:6234–6240.
40. Li ML, Rao P, Krug RM. The active sites of the influenza cap-dependent endonuclease are on different polymerase subunits. EMBO J 2001;20:2078–2086.
41. Shi L, Summers DF, Peng Q, Galarz JM. Influenza A virus RNA polymerase subunit PB2 is the endonuclease which cleaves host cell mRNA and functions only as the trimeric enzyme. Virology 1995;208:38–47.
42. Dias A, Bouvier D, Crépin T, McCarthy AA, Hart DJ, Baudin F, Cusack S, Ruigrok RW. The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature 2009;458:914–918.
43. Yuan P, Bartlam M, Lou Z, Chen S, Zhou J, He X, Lv Z, Ge R, Li X, Deng T, Fodor E, Rao Z, Liu Y. Crystal structure of an avian influenza polymerase PA(N) reveals an endonuclease active site. Nature 2009;458:909–913.
44. Zhao C, Lou Z, Guo Y, Ma M, Chen Y, Liang S, Zhang L, Chen S, Li X, Liu Y, Bartlam M, Rao Z. Nucleoside monophosphate complex structures of the endonuclease domain from the influenza virus polymerase PA subunit reveal the substrate binding site inside the catalytic center. J Virol 2009;83:9024–9030.
45. DuBois RM, Slavish PJ, Baughman BM, Yun MK, Bao J, Webby RJ, Webb TR, White SW. Structural and biochemical basis for development of influenza virus inhibitors targeting the PA endonuclease. PLoS Pathog 2012;8:e1002830.
46. Kowalinski E, Zubieta C, Wolkerstorfer A, Szolar OH, Ruigrok RW, Cusack S. Structural analysis of specific metal chelating inhibitor binding to the endonuclease domain of influenza pH1N1 (2009) polymerase. PLoS Pathog 2012;8:e1002831.
47. Parhi AK, Xiang A, Bauman JD, Patel D, Vijayan RS, Das K, Arnold E, Lavoie EJ. Phenyl substituted 3-hydroxypyridin-2(1H)-ones: Inhibitors of influenza A endonuclease. Bioorg Med Chem 2013;21:6435–6446.
48. Tefsen B, Lu G, Zhu Y, Haywood J, Zhao L, Deng T, Qi J, Gao GF. The N-terminal domain of PA from bat-derived influenza-like virus H17N10 has endonuclease activity. J Virol 2014;88:1935–1941.
49. Song MS, Kumar G, Shadrick WR, Zhou W, Jeevan T, Li Z, Slavish PJ, Fabrizio TP, Yoon SW, Webb TR, Webby RJ, White SW. Identification and characterization of influenza variants resistant to a viral endonuclease inhibitor. Proc Natl Acad Sci USA 2016;113:3669–3674.
50. Bauman JD, Patel D, Baker SF, Vijayan RS, Xiang A, Parhi AK, Martínez-Sobrido L, Lavoie EJ, Das K, Arnold E. Crystallographic fragment screening and structure-based optimization yields a new class of influenza endonuclease inhibitors. ACS Chem Biol 2013;8:2501–2508.
51. Crépin T, Dias A, Palencia A, Swale C, Cusack S, Ruigrok RW. Mutational and metal binding analysis of the endonuclease domain of the influenza virus polymerase PA subunit. J Virol 2010;84:9096–9104.
52. Noble E, Cox A, Deval J, Kim B. Endonuclease substrate selectivity characterized with full-length PA of influenza A virus polymerase. Virology 2012;433:27–34.
53. Maret W. Metalloproteomics, metalloproteomes, and the annotation of metalloproteins. Metallomics 2010;2:117–125.
54. Jahnen-Dechent W, Ketteler M. Magnesium basics. Clin Kidney J 2012;5:i3–i14.
55. Doan L, Handa B, Roberts NA, Klumpp K. Metal ion catalysis of RNA cleavage by the influenza virus endonuclease. Biochemistry 1999;38:5612–5619.
56. Thierry E, Guilligay D, Kosinski J, Bock T, Gaudon S, Round A, Pflug A, Hengrung N, El Omari K, Baudin F, Hart DJ, Beck M, Cusack S. Influenza polymerase can adopt an alternative configuration involving a radical repacking of PB2 domains. Mol Cell 2016;61:125–137.
57. Xiao S, Klein ML, LeBard DN, Levine BG, Liang H, MacDermaid CM, Alfonso-Prieto M. Magnesium-dependent RNA binding to the PA endonuclease domain of the avian influenza polymerase. J Phys Chem B 2014;118:873–889.
58. Hengrung N, El Omari K, Serna M, I, Vreede FT, Cusack S, Rambo RP, Vonrhein C, Bricogne G, Stuart DI, Grimes JM, Fodor E. Crystal structure of the RNA-dependent RNA polymerase from influenza C virus. Nature 2015;527:114–117.
59. Resa-Infante P, Jorba N, Coloma R, Ortín J. The influenza virus RNA synthesis machine: Advances in its structure and function. RNA Biol 2011;8:207–215.
60. Biswas SK, Nayak DP. Mutational analysis of the conserved motifs of influenza A virus polymerase basic protein 1. J Virol 1994;68:1819–1826.
61. Cianci C, Tiley L, Krystal M. Differential activation of the influenza virus polymerase via template RNA binding. J Virol 1995;69:3995–3999.
62. Rao P, Yuan W, Krug RM. Crucial role of CA cleavage sites in the cap-snatching mechanism for initiating viral mRNA synthesis. EMBO J 2003;22:1188–1198.
63. Koppstein D, Ashour J, Bartel DP. Sequencing the cap-snatching repertoire of H1N1 influenza provides insight into the mechanism of viral transcription initiation. Nucleic Acids Res 2015;43:5052–5064.
64. Gu W, Gallagher GR, Dai W, Liu P, Li R, Trombly MI, Gammon DB, Mello CC, Wang JP, Finberg RW. Influenza A virus preferentially snatches noncoding RNA caps. RNA 2015;21:2067–2075.
65. Clohisey S, Bertin N, Wise H, Smith N, Hussain S, Tomiou A, Hu J, Fantom5 Consortium, Carninci P, Forrest A, Hayashizaki Y, Hume D, Digard P, Baillie K. Terminal dept single-molecule sequencing of capped transcripts reveals cap-snatching preferences of influenza A virus in human macrophages. Negative Strand Viruses Meeting; 2015.
66. Shaw MW, Lamb RA. A specific sub-set of host-cell mRNAs prime influenza virus mRNA synthesis. Virus Res 1984;1:455–467.
67. Datta K, Wolkerstorfer A, Szolar OH, Cusack S, Klumpp K. Characterization of PA-N terminal domain of influenza A polymerase reveals sequence specific RNA cleavage. Nucleic Acids Res 2013;41:8289–8299.
68. Stevaert A, Nurra S, Pala N, Carcelli M, Rogolino D, Shepard C, Domaoal RA, Kim B, Alfonso-Prieto M, Marras SAE, Sechi M, Naesens L. An integrated biological approach to guide the development of metal-chelating inhibitors of influenza virus PA endonuclease. Mol Pharmacol 2015;87:323–337.
69. Sikora D, Rocheleau L, Brown EG, Pelchat M. Deep sequencing reveals the eight facets of the influenza A/HongKong/1/1968 (H3N2) virus cap-snatching process. Sci Rep 2014;4:6181.
70. Hagen M, Chung TD, Butcher JA, Krystal M. Recombinant influenza virus polymerase: Requirement of both 5′ and 3′ viral ends for endonuclease activity. J Virol 1994;68:1509–1515.
71. Chung TD, Cianci C, Hagen M, Terry B, Matthews JT, Krystal M, Colonno RJ. Biochemical studies on capped RNA primers identify a class of oligonucleotide inhibitors of the influenza virus RNA polymerase. Proc Natl Acad Sci USA 1994;91:2372–2376.
72. Geerts-Dimitriadou C, Zwart MP, Goldbach R, Kormelink R. Base-pairing promotes leader selection to prime in vitro influenza genome transcription. Virology 2011;409:17–26.
73. Fudo S, Yamamoto N, Nukaga M, Odagiri T, Tashiro M, Hoshino T. Two distinctive binding modes of endonuclease inhibitors to the N-terminal region of influenza virus polymerase acidic subunit. Biochemistry 2016;55:2646–2660.
74. Stevaert A, Dallocchio R, Dessì A, Pala N, Rogolino D, Sechi M, Naesens L. Mutational analysis of the binding pockets of the diketo acid inhibitor L-742,001 in the influenza virus PA endonuclease. J Virol 2013;87:10524–10538.
75. Tomassini JE, Davies ME, Hastings JC, Lingham R, Mojena M, Raghoobar SL, Singh SB, Tkacz JS, Goetz MA. A novel antiviral agent which inhibits the endonuclease of influenza viruses. Antimicrob Agents Chemother 1996;40:1189–1193.
76. Kuzuhara T, Iwai Y, Takahashi H, Hatakeyama D, Echigo N. Green tea catechins inhibit the endonuclease activity of influenza A virus RNA polymerase. PLoS Curr 2009;1:RRN1052.
77. Cianci C, Chung TDY, Meanwell N, Putz H, Hagen M, Colonno RJ, Krystal M. Identification of N-hydroxamic acid and N-hydroxy-imide compounds that inhibit the influenza virus polymerase. Antivir Chem Chemother 1996;7:353–360.
78. Chen E, Swift RV, Alderson N, Feher VA, Feng GS, Amaro RE. Computation-guided discovery of influenza endonuclease inhibitors. ACS Med Chem Lett 2014;5:61–64.
79. Yuan S, Chu H, Singh K, Zhao H, Zhang K, Kao RY, Chow BK, Zhou J, Zheng BJ. A novel small-molecule inhibitor of influenza A virus acts by suppressing PA endonuclease activity of the viral polymerase. Sci Rep 2016;6:22880.
80. Gong P, Peersen OB. Structural basis for active site closure by the poliovirus RNA-dependent RNA polymerase. Proc Natl Acad Sci USA 2010;107:22505–22510.
81. Jorba N, Coloma R, Ortín J. Genetic trans-complementation establishes a new model for influenza virus RNA transcription and replication. PLoS Pathog 2009;5:e1000462.
82. Furuta Y, Takahashi K, Fukuda Y, Kuno-Maekawa M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Watanabe Y, Narita H, Shiraki K. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 2002;46:977–981.
83. Naesens L, Guddat LW, Keough DT, van Kuilenburg AB, Meijer J, Vande Voorde J, Balzarini J. Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir). Mol Pharmacol 2013;84:615–629.
84. Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ, Webster RG, Govorkova EA. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol 2013;87:3741–3751.
85. Cheung PP, Watson SJ, Choy KT, Fun Sia S, Wong DD, Poon LL, Kellam P, Guan Y, Malik Peiris JS, Yen HL. Generation and characterization of influenza A viruses with altered polymerase fidelity. Nat Commun 2014;5:4794.
86. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 1972;177:705–706.
87. Dong SD, Lin CC, Schroeder M. Synthesis and evaluation of a new phosphorylated ribavirin prodrug. Antiviral Res 2013;99:18–26.
88. Sidwell RW, Bailey KW, Wong MH, Barnard DL, Smee DF. In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Res 2005;68:10–17.
89. Pauly MD, Lauring AS. Effective lethal mutagenesis of influenza virus by three nucleoside analogs. J Virol 2015;89:3584–3597.
90. Binh NT, Wakai C, Kawaguchi A, Nagata K. Involvement of the N-terminal portion of influenza virus RNA polymerase subunit PB1 in nucleotide recognition. Biochem Biophys Res Commun 2014;443:975–979.
91. De Clercq E, Cools M, Balzarini J, Snoeck R, Andrei G, Hosoya M, Shigeta S, Ueda T, Minakawa N, Matsuda A. Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide and related compounds. Antimicrob Agents Chemother 1991;35:679–684.
92. Krajczyk A, Kulinska K, Kulinski T, Hurst BL, Day CW, Smee DF, Ostrowski T, Januszczyk P, Zeidler J. Antivirally active ribavirin analogues–4,5-disubstituted 1,2,3-triazole nucleosides: Biological evaluation against certain respiratory viruses and computational modelling. Antivir Chem Chemother 2014;23:161–171.
93. Sidwell RW, Huffman JH, Call EW, Alaghamandan H, Cook PD, Robins RK. Activity of selenazofurin against influenza A and B viruses in vitro. Antimicrob Agents Chemother 1985;28:375–377.
94. Shigeta S, Konno K, Yokota T, Nakamura K, De Clercq E. Comparative activities of several nucleoside analogs against influenza A, B, and C viruses in vitro. Antimicrob Agents Chemother 1988;32:906–911.
95. Colacino JM, DeLong DC, Nelson JR, Spitzer WA, Tang J, Victor F, Wu CY. Evaluation of the anti-influenza virus activities of 1,3,4-thiadiazol-2-ylcyanamide (LY217896) and its sodium salt. Antimicrob Agents Chemother 1990;34:2156–2163.
96. Wang G, Wan J, Hu Y, Wu X, Prhavc M, Dyatkina N, Rajwanshi VK, Smith DB, Jekle A, Kinkade A, Symons JA, Jin Z, Deval J, Zhang Q, Tam Y, Chanda S, Blatt L, Beigelman L. Synthesis and anti-influenza activity of pyridine, pyridazine, and pyrimidine C-nucleosides as favipiravir (T-705) analogues. J Med Chem 2016;59:4611–4624.
97. Gao J, Luo X, Li Y, Gao R, Chen H, Ji D. Synthesis and biological evaluation of 2-oxo-pyrazine-3-carboxamide-yl nucleoside analogues and their epimers as inhibitors of influenza A viruses. Chem Biol Drug Des 2015;85:245–252.
98. Tisdale M, Appleyard G, Tuttle JV, Nelson DJ, Nusinoff-Lehrman S, Al Nakib W, Stables JN, Purifoy DJM, Powell KL, Darby G. Inhibition of influenza A and B viruses by 2′-deoxy-2′-fluororibosides. Antivir Chem Chemother 1993;4:281–287.
99. Rollins BS, Elkhatieb AH, Hayden FG. Comparative anti-influenza virus activity of 2′-deoxy-2′-fluororibosides in vitro. Antiviral Res 1993;21:357–368.
100. Abdel-Magid AF. Influenza RNA-dependent RNA polymerase (RdRp) inhibitors: potential new therapy for influenza treatment. ACS Med Chem Lett 2013;4:1133–1134.
101. Baughman BM, Jake Slavish P, DuBois RM, Boyd VA, White SW, Webb TR. Identification of influenza endonuclease inhibitors using a novel fluorescence polarization assay. ACS Chem Biol 2012;7:526–534.
102. Vedula MS, Jennepalli S, Aryasomayajula R, Rondla SR, Musku MR, Kura RR, Bandi PR. Novel nucleosides as potent influenza viral inhibitors. Bioorg Med Chem 2010;18:6329–6339.
103. Lin C, Sun C, Liu X, Zhou Y, Hussain M, Wan J, Li M, Li X, Jin R, Tu Z, Zhang J. Design, synthesis, and in vitro biological evaluation of novel 6-methyl-7-substituted-7-deaza purine nucleoside analogs as anti-influenza A agents. Antiviral Res 2016;129:13–20.
104. Meneghesso S, Vanderlinden E, Brancale A, Balzarini J, Naesens L, McGuigan C. Synthesis and biological evaluation of purine 2′-fluoro-2′-deoxyriboside ProTides as anti-influenza virus agents. ChemMedChem 2013;8:415–425.
105. Kumaki Y, Day CW, Smee DF, Morrey JD, Barnard DL. In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections. Antiviral Res 2011;92:329–340.
106. Meneghesso S, Vanderlinden E, Stevaert A, McGuigan C, Balzarini J, Naesens L. Synthesis and biological evaluation of pyrimidine nucleoside monophosphate prodrugs targeted against influenza virus. Antiviral Res 2012;94:35–43.
107. Hoffmann HH, Kunz A, Simon VA, Palese P, Shaw ML. Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci USA 2011;108:5777–5782.
108. Smee DF, McKernan PA, Nord LD, Willis RC, Petrie CR, Riley TM, Revankar GR, Robins RK, Smith RA. Novel pyrazolo[3,4-d]pyrimidine nucleoside analog with broad-spectrum antiviral activity. Antimicrob Agents Chemother 1987;31:1535–1541.
109. Shannon WM, Arnett G, Westbrook L, Shealy YF, O'Dell CA, Brockman RW. Evaluation of carbodine, the carbocyclic analog of cytidine, and related carbocyclic analogs of pyrimidine nucleosides for antiviral activity against human influenza type A viruses. Antimicrob Agents Chemother 1981;20:769–776.
110. Rao JR, Jha AK, Rawal RK, Sharon A, Day CW, Barnard DL, Smee DF, Chu CK. (-)-Carbodine: Enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu). Bioorg Med Chem Lett 2010;20:2601–2604.
111. Su CY, Cheng TJ, Lin MI, Wang SY, Huang WI, Lin-Chu SY, Chen YH, Wu CY, Lai MM, Cheng WC, Wu YT, Tsai MD, Cheng YS, Wong CH. High-throughput identification of compounds targeting influenza RNA-dependent RNA polymerase activity. Proc Natl Acad Sci USA 2010;107:19151–19156.
112. Ortigoza MB, Dibben O, Maamary J, Martínez-Gil L, Leyva-Grado VH, Abreu P Jr, Ayllon J, Palese P, Shaw ML. A novel small molecule inhibitor of influenza A viruses that targets polymerase function and indirectly induces interferon. PLoS Pathog 2012;8:e1002668.
113. Byrn RA, Jones SM, Bennett HB, Bral C, Clark MP, Jacobs MD, Kwong AD, Ledeboer MW, Leeman JR, McNeil CF, Murcko MA, Nezami A, Perola E, Rijnbrand R, Saxena K, Tsai AW, Zhou Y, Charifson PS. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob Agents Chemother 2015;59:1569–1582.
114. Roch FF, Hinterkorner G, Menke J, Tang GQ, Cusack S, Butzendobler B, Buschmann H, Datta K, Wolkerstorfer A. An RNA hybridization assay for screening influenza A virus polymerase inhibitors using the entire ribonucleoprotein complex. Assay Drug Dev Technol 2015;13:488–506.
115. 7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds. Antimicrob Agents Chemother 1994;38:2827–2837.
116. Hastings JC, Selnick H, Wolanski B, Tomassini JE. Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid inhibitors. Antimicrob Agents Chemother 1996;40:1304–1307.
117. Nakazawa M, Kadowaki SE, Watanabe I, Kadowaki Y, Takei M, Fukuda H. PA subunit of RNA polymerase as a promising target for anti-influenza virus agents. Antiviral Res 2008;78:194–201.
118. Parkes KE, Ermert P, Fässler J, Ives J, Martin JA, Merrett JH, Obrecht D, Williams G, Klumpp K. Use of a pharmacophore model to discover a new class of influenza endonuclease inhibitors. J Med Chem 2003;46:1153–1164.
119. Iwai Y, Takahashi H, Hatakeyama D, Motoshima K, Ishikawa M, Sugita K, Hashimoto Y, Harada Y, Itamura S, Odagiri T, Tashiro M, Sei Y, Yamaguchi K, Kuzuhara T. Anti-influenza activity of phenethylphenylphthalimide analogs derived from thalidomide. Bioorg Med Chem 2010;18:5379–5390.
120. Fudo S, Yamamoto N, Nukaga M, Odagiri T, Tashiro M, Neya S, Hoshino T. Structural and computational study on inhibitory compounds for endonuclease activity of influenza virus polymerase. Bioorg Med Chem 2015;23:5466–5475.
121. Pala N, Stevaert A, Dallocchio R, Dessì A, Rogolino D, Carcelli M, Sanna V, Sechi M, Naesens L. Virtual screening and biological validation of novel influenza virus PA endonuclease inhibitors. ACS Med Chem Lett 2015;6:866–871.
122. Yamada K, Koyama H, Hagiwara K, Ueda A, Sasaki Y, Kanesashi SN, Ueno R, Nakamura HK, Kuwata K, Shimizu K, Suzuki M, Aida Y. Identification of a novel compound with antiviral activity against influenza A virus depending on PA subunit of viral RNA polymerase. Microbes Infect 2012;14:740–747.
123. Yuan S, Zhang N, Singh K, Shuai H, Chu H, Zhou J, Chow BK, Zheng BJ. Cross-protection of influenza A virus infection by a DNA aptamer targeting the PA endonuclease domain. Antimicrob Agents Chemother 2015;59:4082–4093.
124. Kessler U, Castagnolo D, Pagano M, Deodato D, Bernardini M, Pilger B, Ranadheera C, Botta M. Discovery and synthesis of novel benzofurazan derivatives as inhibitors of influenza A virus. Bioorg Med Chem Lett 2013;23:5575–5577.
125. Pagano M, Castagnolo D, Bernardini M, Fallacara AL, Laurenzana I, Deodato D, Kessler U, Pilger B, Stergiou L, Strunze S, Tintori C, Botta M. The fight against the influenza A virus H1N1: Synthesis, molecular modeling, and biological evaluation of benzofurazan derivatives as viral RNA polymerase inhibitors. ChemMedChem 2014;9:129–150.
126. Fukuoka M, Minakuchi M, Kawaguchi A, Nagata K, Kamatari YO, Kuwata K. Structure-based discovery of anti-influenza virus A compounds among medicines. Biochim Biophys Acta 2012;1820:90–95.
127. Muratore G, Goracci L, Mercorelli B, Foeglein Á, Digard P, Cruciani G, Palù G, Loregian A. Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase. Proc Natl Acad Sci USA 2012;109:6247–6252.
128. Muratore G, Mercorelli B, Goracci L, Cruciani G, Digard P, Palù G, Loregian A. Human cytomegalovirus inhibitor AL18 also possesses activity against influenza A and B viruses. Antimicrob Agents Chemother 2012;56:6009–6013.
129. Massari S, Nannetti G, Goracci L, Sancineto L, Muratore G, Sabatini S, Manfroni G, Mercorelli B, Cecchetti V, Facchini M, Palù G, Cruciani G, Loregian A, Tabarrini O. Structural investigation of cycloheptathiophene-3-carboxamide derivatives targeting influenza virus polymerase assembly. J Med Chem 2013;56:10118–10131.
130. Lepri S, Nannetti G, Muratore G, Cruciani G, Ruzziconi R, Mercorelli B, Palù G, Loregian A, Goracci L. Optimization of small-molecule inhibitors of influenza virus polymerase: from thiophene-3-carboxamide to polyamido scaffolds. J Med Chem 2014;57:4337–4350.
131. Massari S, Nannetti G, Desantis J, Muratore G, Sabatini S, Manfroni G, Mercorelli B, Cecchetti V, Palù G, Cruciani G, Loregian A, Goracci L, Tabarrini O. A broad anti-influenza hybrid small molecule that potently disrupts the interaction of Polymerase Acidic Protein-Basic Protein 1 (PA-PB1) subunits. J Med Chem 2015;58:3830–3842.
132. Trist IM, Nannetti G, Tintori C, Fallacara AL, Deodato D, Mercorelli B, Palù G, Wijtmans M, Gospodova T, Edink E, Verheij M, de Esch I, Viteva L, Loregian A, Botta M. 4,6-Diphenylpyridines as promising novel anti-influenza agents targeting the PA-PB1 protein-protein interaction: Structure-activity relationships exploration with the aid of molecular modeling. J Med Chem 2016;59:2688–2703.
133. Yuan S, Chu H, Zhao H, Zhang K, Singh K, Chow BK, Kao RY, Zhou J, Zheng BJ. Identification of a small-molecule inhibitor of influenza virus via disrupting the subunits interaction of the viral polymerase. Antiviral Res 2016;125:34–42.
134. Kao RY, Yang D, Lau LS, Tsui WH, Hu L, Dai J, Chan MP, Chan CM, Wang P, Zheng BJ, Sun J, Huang JD, Madar J, Chen G, Chen H, Guan Y, Yuen KY. Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol 2010;28:600–605.
135. Gerritz SW, Cianci C, Kim S, Pearce BC, Deminie C, Discotto L, McAuliffe B, Minassian BF, Shi S, Zhu S, Zhai W, Pendri A, Li G, Poss MA, Edavettal S, McDonnell PA, Lewis HA, Maskos K, Mörtl M, Kiefersauer R, Steinbacher S, Baldwin ET, Metzler W, Bryson J, Healy MD, Philip T, Zoeckler M, Schartman R, Sinz M, Leyva-Grado VH, Hoffmann HH, Langley DR, Meanwell NA, Krystal M. Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers. Proc Natl Acad Sci USA 2011;108:15366–15371.
136. Cianci C, Gerritz SW, Deminie C, Krystal M. Influenza nucleoprotein: Promising target for antiviral chemotherapy. Antivir Chem Chemother 2013;23:77–91.
137. Lin MI, Su BH, Lee CH, Wang ST, Wu WC, Dangate P, Wang SY, Huang WI, Cheng TJ, Lin OA, Cheng YE, Tseng YJ, Sun CM. Synthesis and inhibitory effects of novel pyrimido-pyrrolo-quinoxalinedione analogues targeting nucleoproteins of influenza A virus H1N1. Eur J Med Chem 2015;102:477–486.
138. Shen YF, Chen YH, Chu SY, Lin MI, Hsu HT, Wu PY, Wu CJ, Liu HW, Lin FY, Lin G, Hsu PH, Yang AS, Cheng YS, Wu YT, Wong CH, Tsai MD. E339…R416 salt bridge of nucleoprotein as a feasible target for influenza virus inhibitors. Proc Natl Acad Sci USA 2011;108:16515–16520.
139. Lejal N, Tarus B, Bouguyon E, Chenavas S, Bertho N, Delmas B, Ruigrok RW, Di Primo C, Slama-Schwok A. Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus. Antimicrob Agents Chemother 2013;57:2231–2242.
140. Fedichev P, Timakhov R, Pyrkov T, Getmantsev E, Vinnik A. Structure-based drug design of a new chemical class of small molecules active against influenza A nucleoprotein in vitro and in vivo. PLoS Curr 2011;3:RRN1253.
141. Kakisaka M, Sasaki Y, Yamada K, Kondoh Y, Hikono H, Osada H, Tomii K, Saito T, Aida Y. A novel antiviral target structure involved in the RNA binding, dimerization, and nuclear export functions of the influenza A virus nucleoprotein. PLoS Pathog 2015;11:e1005062.
142. Hagiwara K, Kondoh Y, Ueda A, Yamada K, Goto H, Watanabe T, Nakata T, Osada H, Aida Y. Discovery of novel antiviral agents directed against the influenza A virus nucleoprotein using photo-cross-linked chemical arrays. Biochem Biophys Res Commun 2010;394:721–727.
143. Leneva IA, Fediakina IT, Eropkin MI, Gudova NV, Romanovskaia AA, Danilenko DM, Vinogradova SM, Lepeshkin AI, Shestopalov AM. [Study of the antiviral activity of Russian anti-influenza agents in cell culture and animal models]. Vopr Virusol 2010;55:19–27.
144. Semenova NP, Prokudina EN, Livov DK, Nebol'sin VE. Effect of the antiviral drug Ingaviruin on intracellular transformations and import into the nucleus of influenza A virus nucleocapsid protein. Vopr Virusol 2010;55:17–20.
145. Zarubaev VV, Garshinina AV, Kalinina NA, Shtro AA, Belyaevskaya SV, Slita AV, Nebolsin VE, Kiselev OI. Activity of Ingavirin (6-[2-(1H-imidazol-4-yl)ethylamino]-5-oxo-hexanoic acid) against human respiratory viruses in in vivo experiments. Pharmaceuticals 2011;4:1518–1534.
146. nd European Congress of Clinical Microbiology and Infectious Diseases; 2012.
147. Perwitasari O, Johnson S, Yan X, Howerth E, Shacham S, Landesman Y, Baloglu E, McCauley D, Tamir S, Tompkins SM, Tripp RA. Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo. J Virol 2014;88:10228–10243.
148. Hsu JT, Yeh JY, Lin TJ, Li ML, Wu MS, Hsieh CF, Chou YC, Tang WF, Lau KS, Hung HC, Fang MY, Ko S, Hsieh HP, Horng JT. Identification of BPR3P0128 as an inhibitor of cap-snatching activities of influenza virus. Antimicrob Agents Chemother 2012;56:647–657.
149. Lee MK, Bottini A, Kim M, Bardaro MF, Jr, Zhang Z, Pellecchia M, Choi BS, Varani G. A novel small-molecule binds to the influenza A virus RNA promoter and inhibits viral replication. Chem Commun (Camb) 2014;50:368–370.
150. Chase G, Deng T, Fodor E, Leung BW, Mayer D, Schwemmle M, Brownlee G. Hsp90 inhibitors reduce influenza virus replication in cell culture. Virology 2008;377:431–439.
151. Ozawa M, Shimojima M, Goto H, Watanabe S, Hatta Y, Kiso M, Furuta Y, Horimoto T, Peters NR, Hoffmann FM, Kawaoka Y. A cell-based screening system for influenza A viral RNA transcription/replication inhibitors. Sci Rep 2013;3:1106.
152. Pascua PN, Lee JH, Song MS, Park SJ, Baek YH, Ann BH, Shin EY, Kim EG, Choi YK. Role of the p21-activated kinases (PAKs) in influenza A virus replication. Biochem Biophys Res Commun 2011;414:569–574.
153. Droebner K, Pleschka S, Ludwig S, Planz O. Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo. Antiviral Res 2011;92:195–203.
154. Haasbach E, Hartmayer C, Planz O. Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro. Antiviral Res 2013;98:319–324.
155. Sasaki Y, Kakisaka M, Chutiwitoonchai N, Tajima S, Hikono H, Saito T, Aida Y. Identification of a novel multiple kinase inhibitor with potent antiviral activity against influenza virus by reducing viral polymerase activity. Biochem Biophys Res Commun 2014;450:49–54.
156. Mazur I, Wurzer WJ, Ehrhardt C, Pleschka S, Puthavathana P, Silberzahn T, Wolff T, Planz O, Ludwig S. Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity. Cell Microbiol 2007;9:1683–1694.
157. Wiesener N, Zimmer C, Jarasch-Althof N, Wutzler P, Henke A. Therapy of experimental influenza virus infection with pyrrolidine dithiocarbamate. Med Microbiol Immunol 2011;200:115–126.
158. Ehrhardt C, Rückle A, Hrincius ER, Haasbach E, Anhlan D, Ahmann K, Banning C, Reiling SJ, Kühn J, Strobl S, Vitt D, Leban J, Planz O, Ludwig S. The NF-kappaB inhibitor SC75741 efficiently blocks influenza virus propagation and confers a high barrier for development of viral resistance. Cell Microbiol 2013;15:1198–1211.
159. Pinto R, Herold S, Cakarova L, Hoegner K, Lohmeyer J, Planz O, Pleschka S. Inhibition of influenza virus-induced NF-kappaB and Raf/MEK/ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and in vivo. Antiviral Res 2011;92:45–56.
160. Dierkes R, Warnking K, Liedmann S, Seyer R, Ludwig S, Ehrhardt C. The Rac1 inhibitor NSC23766 exerts anti-influenza virus properties by affecting the viral polymerase complex activity. PLoS One 2014;9:e88520.
161. Tisdale M, Ellis M, Klumpp K, Court S, Ford M. Inhibition of influenza virus transcription by 2′-deoxy-2′-fluoroguanosine. Antimicrob Agents Chemother 1995;39:2454–2458.
162. Sugiyama K, Kawaguchi A, Okuwaki M, Nagata K. pp32 and APRIL are host cell-derived regulators of influenza virus RNA synthesis from cRNA. Elife 2015;4.
163. Vreede FT, Chan AY, Sharps J, Fodor E. Mechanisms and functional implications of the degradation of host RNA polymerase II in influenza virus infected cells. Virology 2010;396:125–134.
164. Watanabe T, Kawaoka Y. Influenza virus-host interactomes as a basis for antiviral drug development. Curr Opin Virol 2015;14:71–78.
165. Cohen A, Togo Y, Khakoo R, Waldman R, Sigel M. Comparative clinical and laboratory evaluation of the prophylactic capacity of ribavirin, amantadine hydrochloride, and placebo in induced human influenza type A. J Infect Dis 1976;133(Suppl):A114–A120.
166. Stein DS, Creticos CM, Jackson GG, Bernstein JM, Hayden FG, Schiff GM, Bernstein DI. Oral ribavirin treatment of influenza A and B. Antimicrob Agents Chemother 1987;31:1285–1287.
167. Ilyushina NA, Hay A, Yilmaz N, Boon AC, Webster RG, Govorkova EA. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother 2008;52:3889–3897.
168. NIH. National Library of Medicine (US). Hazardous Substances Data Bank. Ribavirin. Hazardous Substances Databank Number: 6513. http://toxnet.nlm.nih.gov/.
169. van der Vries E, Stelma FF, Boucher CA. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med 2010;363:1381–1382.
170. Willis RC, Carson DA, Seegmiller JE. Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line. Proc Natl Acad Sci USA 1978;75:3042–3044.
171. Wu JZ, Larson G, Walker H, Shim JH, Hong Z. Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5′-nucleotidase II: Implications for ribavirin metabolism in erythrocytes. Antimicrob Agents Chemother 2005;49:2164–2171.
172. Streeter DG, Witkowski JT, Khare GP, Sidwell RW, Bauer RJ, Robins RK, Simon LN. Mechanism of action of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci USA 1973;70:1174–1178.
173. Wray SK, Gilbert BE, Noall MW, Knight V. Mode of action of ribavirin: Effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. Antiviral Res 1985;5:29–37.
174. Robins RK, Revankar GR, McKernan PA, Murray BK, Kirsi JJ, North JA. The importance of IMP dehydrogenase inhibition in the broad spectrum antiviral activity of ribavirin and selenazofurin. Adv Enzyme Regul 1985;24:29–43.
175. Scholtissek C. Inhibition of influenza RNA synthesis by virazole (ribavirin). Arch Virol 1976;50:349–352.
176. Eriksson B, Helgstrand E, Johansson NG, Larsson A, Misiorny A, Norén JO, Philipson L, Stenberg K, Stening G, Stridh S, Oberg B. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob Agents Chemother 1977;11:946–951.
177. Graci JD, Cameron CE. Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol 2006;16:37–48.
178. Witkowski JT, Robins RK, Khare GP, Sidwell RW. Synthesis and antiviral activity of 1,2,4-triazole-3-thiocarboxamide and 1,2,4-triazole-3-carboxamidine ribonucleosides. J Med Chem 1973;16:935–937.
179. De Clercq E, Luczak M. Fluoroimidazoles as antiviral agents and inhibitors of polynucleotide biosynthesis. Life Sci 1975;17:187–194.
180. Minakawa N, Matsuda A. Mechanism-based design of inosine 5-monophosphate dehydrogenase inhibitors: Synthesis and biological activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide (EICAR) and its derivatives. Curr Med Chem 1999;6:615–628.
181. Birch GM, Colacino JM, Ehlhardt WJ, Balzarini J. The intracellular formation of a mononucleotide of the anti-influenza agent 1,3,4-thiadiazol-2-ylcyanamide (LY217896). Antivir Chem Chemother 1995;6:127–137.
182. Hayden FG, Tunkel AR, Treanor JJ, Betts RF, Allerheiligen S, Harris J. Oral LY217896 for prevention of experimental influenza A virus infection and illness in humans. Antimicrob Agents Chemother 1994;38:1178–1181.
183. Zumla A, Memish ZA, Maeurer M, Bates M, Mwaba P, Al-Tawfiq JA, Denning DW, Hayden FG, Hui DS. Emerging novel and antimicrobial-resistant respiratory tract infections: New drug development and therapeutic options. Lancet Infect Dis 2014;14:1136–1149.
184. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, Muramoto Y, Tamura D, Sakai-Tagawa Y, Noda T, Sakabe S, Imai M, Hatta Y, Watanabe S, Li C, Yamada S, Fujii K, Murakami S, Imai H, Kakugawa S, Ito M, Takano R, Iwatsuki-Horimoto K, Shimojima M, Horimoto T, Goto H, Takahashi K, Makino A, Ishigaki H, Nakayama M, Okamatsu M, Takahashi K, Warshauer D, Shult PA, Saito R, Suzuki H, Furuta Y, Yamashita M, Mitamura K, Nakano K, Nakamura M, Brockman-Schneider R, Mitamura H, Yamazaki M, Sugaya N, Suresh M, Ozawa M, Neumann G, Gern J, Kida H, Ogasawara K, Kawaoka Y. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009;460:1021–1025.
185. Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S, Le QM, Ozawa M, Furuta Y, Kawaoka Y. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci USA 2010;107:882–887.
186. Cao RY, Xiao JH, Cao B, Li S, Kumaki Y, Zhong W. Inhibition of novel reassortant avian influenza H7N9 virus infection in vitro with three antiviral drugs, oseltamivir, peramivir and favipiravir. Antivir Chem Chemother 2013.
187. Sleeman K, Mishin VP, Deyde VM, Furuta Y, Klimov AI, Gubareva LV. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob Agents Chemother 2010;54:2517–2524.
188. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H, Shiraki K. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 2005;49:981–986.
189. Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J. The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5′-triphosphate towards influenza A virus polymerase. PLoS One 2013;8:e68347.
190. Sangawa H, Komeno T, Nishikawa H, Yoshida A, Takahashi K, Nomura N, Furuta Y. Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob Agents Chemother 2013;57:5202–5208.
191. Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 2009;82:95–102.
192. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013;100:446–454.
193. Jakeman KJ, Tisdale M, Russell S, Leone A, Sweet C. Efficacy of 2′-deoxy-2′-fluororibosides against influenza A and B viruses in ferrets. Antimicrob Agents Chemother 1994;38:1864–1867.
194. Mehellou Y, Balzarini J, McGuigan C. Aryloxy phosphoramidate triesters: A technology for delivering monophosphorylated nucleosides and sugars into cells. ChemMedChem 2009;4:1779–1791.
195. Stuyver LJ, McBrayer TR, Whitaker T, Tharnish PM, Ramesh M, Lostia S, Cartee L, Shi J, Hobbs A, Schinazi RF, Watanabe KA, Otto MJ. Inhibition of the subgenomic hepatitis C virus replicon in huh-7 cells by 2′-deoxy-2′-fluorocytidine. Antimicrob Agents Chemother 2004;48:651–654.
196. Denisova OV, Kakkola L, Feng L, Stenman J, Nagaraj A, Lampe J, Yadav B, Aittokallio T, Kaukinen P, Ahola T, Kuivanen S, Vapalahti O, Kantele A, Tynell J, Julkunen I, Kallio-Kokko H, Paavilainen H, Hukkanen V, Elliott RM, De Brabander JK, Saelens X, Kainov DE. Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza A virus infection. J Biol Chem 2012;287:35324–35332.
197. Shannon WM, Arnett G, Westbrook L, Shealy YF, O'Dell CA, Brockman RW. Evaluation of carbodine, the carbocyclic analog of cytidine, and related carbocyclic analogs of pyrimidine nucleosides for antiviral activity against human influenza type A viruses. Antimicrob Agents Chemother 1981;20:769–776.
198. De Clercq E, Bernaerts R, Shealy YF, Montgomery JA. Broad-spectrum antiviral activity of carbodine, the carbocyclic analogue of cytidine. Biochem Pharmacol 1990;39:319–325.
199. De Clercq E, Murase J, Marquez VE. Broad-spectrum antiviral and cytocidal activity of cyclopentenylcytosine, a carbocyclic nucleoside targeted at CTP synthetase. Biochem Pharmacol 1991;41:1821–1829.
200. Shealy YF, O'Dell CA, Arnett G. Synthesis and antiviral evaluation of carbocyclic analogues of 2-amino-6-substituted-purine 3′-deoxyribofuranosides. J Med Chem 1987;30:1090–1094.
201. Streeter DG, Koyama HH. Inhibition of purine nucleotide biosynthesis by 3-deazaguanine, its nucleoside and 5′-nucleotide. Biochem Pharmacol 1976;25:2413–2415.
202. Fung A, Jin Z, Dyatkina N, Wang G, Beigelman L, Deval J. Efficiency of incorporation and chain termination determines the inhibition potency of 2′-modified nucleotide analogs against hepatitis C virus polymerase. Antimicrob Agents Chemother 2014;58:3636–3645.
203. Sofia MJ, Chang W, Furman PA, Mosley RT, Ross BS. Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase. J Med Chem 2012;55:2481–2531.
204. Wang G, Deval J, Hong J, Dyatkina N, Prhavc M, Taylor J, Fung A, Jin Z, Stevens SK, Serebryany V, Liu J, Zhang Q, Tam Y, Chanda SM, Smith DB, Symons JA, Blatt LM, Beigelman L. Discovery of 4′-chloromethyl-2′-deoxy-3′,5′-di-O-isobutyryl-2′-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. J Med Chem 2015;58:1862–1878.
205. de la Luna S, Martínez C, Ortín J. Molecular cloning and sequencing of influenza virus A/Victoria/3/75 polymerase genes: Sequence evolution and prediction of possible functional domains. Virus Res 1989;13:143–155.
206. Boyd MJ, Bandarage UK, Bennett H, Byrn RR, Davies I, Gu W, Jacobs M, Ledeboer MW, Ledford B, Leeman JR, Perola E, Wang T, Bennani Y, Clark MP, Charifson PS. Isosteric replacements of the carboxylic acid of drug candidate VX-787: Effect of charge on antiviral potency and kinase activity of azaindole-based influenza PB2 inhibitors. Bioorg Med Chem Lett 2015;25:1990–1994.
207. Byrn RA, Jones SM, Bennett HB, Bral C, Clark MP, Jacobs MD, Kwong AD, Ledeboer MW, Leeman JR, McNeil CF, Murcko MA, Nezami A, Perola E, Rijnbrand R, Saxena K, Tsai AW, Zhou Y, Charifson PS. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob Agents Chemother 2015;59:1569–1582.
208. Severin C, Rocha de Moura T, Liu Y, Li K, Zheng X, Luo M. The cap-binding site of influenza virus protein PB2 as a drug target. Acta Crystallogr D Struct Biol 2016;72:245–253.
209. Metifiot M, Marchand C, Pommier Y. HIV integrase inhibitors: 20-Year landmark and challenges. Adv Pharmacol 2013;67:75–105.
210. Kirschberg T, Parrish J. Metal chelators as antiviral agents. Curr Opin Drug Discov Dev 2007;10:460–472.
211. Blair W, Cox C. Current landscape of antiviral drug discovery. F1000Research 2016;5:F1000.
212. Singh SB, Tomassini JE. Synthesis of natural flutimide and analogous fully substituted pyrazine-2,6-diones, endonuclease inhibitors of influenza virus. J Org Chem 2001;66:5504–5516.
213. Iwai Y, Murakami K, Gomi Y, Hashimoto T, Asakawa Y, Okuno Y, Ishikawa T, Hatakeyama D, Echigo N, Kuzuhara T. Anti-influenza activity of marchantins, macrocyclic bisbibenzyls contained in liverworts. PLoS One 2011;6:e19825.
214. 60 fullerene derivatives. PLoS One 2013;8:e66337.
215. Sagong HY, Parhi A, Bauman JD, Patel D, Vijayan RSK, Das K, Arnold E, LaVoie EJ. 3-hydroxyquinolin-2(1H)-ones as inhibitors of influenza A endonuclease. ACS Med Chem Lett 2013;4:547–550.
216. Sagong HY, Bauman JD, Patel D, Das K, Arnold E, Lavoie EJ. Phenyl substituted 4-hydroxypyridazin-3(2H)-ones and 5-hydroxypyrimidin-4(3H)-ones: Inhibitors of influenza A endonuclease. J Med Chem 2014;57:8086–8098.
217. Carcelli M, Rogolino D, Bacchi A, Rispoli G, Fisicaro E, Compari C, Sechi M, Stevaert A, Naesens L. Metal-chelating 2-hydroxyphenyl amide pharmacophore for inhibition of influenza virus endonuclease. Mol Pharm 2014;11:304–316.
218. Rogolino D, Bacchi A, De Luca L, Rispoli G, Sechi M, Stevaert A, Naesens L, Carcelli M. Investigation of the salicylaldehyde thiosemicarbazone scaffold for inhibition of influenza virus PA endonuclease. J Biol Inorg Chem 2015;20:1109–1121.
219. Rogolino D, Carcelli M, Sechi M, Neamati N. Viral enzymes containing magnesium: Metal binding as a successful strategy in drug design. Coord Chem Rev 2012;256:3063–3086.
220. Marchand C, Johnson AA, Karki RG, Pais GC, Zhang X, Cowansage K, Patel TA, Nicklaus MC, Burke TR, Jr, Pommier Y. Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S). Mol Pharmacol 2003;64:600–609.
221. Bock CW, Kaufman Katz A, Markham GD, Glusker JP. Manganese as a replacement for magnesium and zinc: Functional comparison of the divalent ions. J Am Chem Soc 1999;121:7360–7372.
222. Tchertanov L, Mouscadet JF. Target recognition by catechols and beta-ketoenols: Potential contribution of hydrogen bonding and Mn/Mg chelation to HIV-1 integrase inhibition. J Med Chem 2007;50:1133–1145.
223. He X, Zhou J, Bartlam M, Zhang R, Ma J, Lou Z, Li X, Li J, Joachimiak A, Zeng Z, Ge R, Rao Z, Liu Y. Crystal structure of the polymerase PA(C)-PB1(N) complex from an avian influenza H5N1 virus. Nature 2008;454:1123–1126.
224. Moen SO, Abendroth J, Fairman JW, Baydo RO, Bullen J, Kirkwood JL, Barnes SR, Raymond AC, Begley DW, Henkel G, McCormack K, Tam VC, Phan I, Staker BL, Stacy R, Myler PJ, Lorimer D, Edwards TE. Structural analysis of H1N1 and H7N9 influenza A virus PA in the absence of PB1. Sci Rep 2014;4:5944.
225. Sugiyama K, Obayashi E, Kawaguchi A, Suzuki Y, Tame JR, Nagata K, Park SY. Structural insight into the essential PB1-PB2 subunit contact of the influenza virus RNA polymerase. EMBO J 2009;28:1803–1811.
226. Obayashi E, Yoshida H, Kawai F, Shibayama N, Kawaguchi A, Nagata K, Tame JR, Park SY. The structural basis for an essential subunit interaction in influenza virus RNA polymerase. Nature 2008;454:1127–1131.
227. Rognan D. Rational design of protein-protein interaction inhibitors. Med Chem Commun 2015;6:51–60.
228. Ghanem A, Mayer D, Chase G, Tegge W, Frank R, Kochs G, García-Sastre A, Schwemmle M. Peptide-mediated interference with influenza A virus polymerase. J Virol 2007;81:7801–7804.
229. Wunderlich K, Mayer D, Ranadheera C, Holler AS, Mänz B, Martin A, Chase G, Tegge W, Frank R, Kessler U, Schwemmle M. Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. PLoS One 2009;4:e7517.
230. Wunderlich K, Juozapaitis M, Ranadheera C, Kessler U, Martin A, Eisel J, Beutling U, Frank R, Schwemmle M. Identification of high-affinity PB1-derived peptides with enhanced affinity to the PA protein of influenza A virus polymerase. Antimicrob Agents Chemother 2011;55:696–702.
231. Tintori C, Laurenzana I, Fallacara AL, Kessler U, Pilger B, Stergiou L, Botta M. High-throughput docking for the identification of new influenza A virus polymerase inhibitors targeting the PA-PB1 protein-protein interaction. Bioorg Med Chem Lett 2014;24:280–282.
232. Massari S, Goracci L, Desantis J, Tabarrini O. Polymerase acidic protein-basic protein 1 (PA-PB1) protein-protein interaction as a target for next-generation anti-influenza therapeutics. J Med Chem 2016. In press.
233. Chase G, Wunderlich K, Reuther P, Schwemmle M. Identification of influenza virus inhibitors which disrupt of viral polymerase protein-protein interactions. Methods 2011;55:188–191.
234. Li C, Ba Q, Wu A, Zhang H, Deng T, Jiang T. A peptide derived from the C-terminus of PB1 inhibits influenza virus replication by interfering with viral polymerase assembly. FEBS J 2013;280:1139–1149.
235. Reuther P, Mänz B, Brunotte L, Schwemmle M, Wunderlich K. Targeting of the influenza A virus polymerase PB1-PB2 interface indicates strain-specific assembly differences. J Virol 2011;85:13298–13309.
236. U.S. National Library of Medicine. Information on clinical trials and human research studies: Testing the AVI-7100 flu drug in healthy volunteers. https://clinicaltrials.gov/ct2/show/NCT01747148.
237. Barik S. siRNA for influenza therapy. Viruses 2010;2:1448–1457.
238. Ge Q, McManus MT, Nguyen T, Shen CH, Sharp PA, Eisen HN, Chen J. RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc Natl Acad Sci USA 2003;100:2718–2723.
239. Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci USA 2004;101:8676–8681.
240. Lin L, Liu Q, Berube N, Detmer S, Zhou Y. 5′-Triphosphate-short interfering RNA: Potent inhibition of influenza A virus infection by gene silencing and RIG-I activation. J Virol 2012;86:10359–10369.
241. Xu F, Liu G, Liu Q, Zhou Y. RNA interference of influenza A virus replication by microRNA-adapted lentiviral loop short hairpin RNA. J Gen Virol 2015;96:2971–2981.
242. Linke LM, Wilusz J, Pabilonia KL, Fruehauf J, Magnuson R, Olea-Popelka F, Triantis J, Landolt G, Salman M. Inhibiting avian influenza virus shedding using a novel RNAi antiviral vector technology: Proof of concept in an avian cell model. AMB Express 2016;6:16.
243. Biswas SK, Boutz PL, Nayak DP. Influenza virus nucleoprotein interacts with influenza virus polymerase proteins. J Virol 1998;72:5493–5501.
244. Poole E, Elton D, Medcalf L, Digard P. Functional domains of the influenza A virus PB2 protein: Identification of NP- and PB1-binding sites. Virology 2004;321:120–133.
245. Marklund JK, Ye Q, Dong J, Tao YJ, Krug RM. Sequence in the influenza A virus nucleoprotein required for viral polymerase binding and RNA synthesis. J Virol 2012;86:7292–7297.
246. Ye Q, Krug RM, Tao YJ. The mechanism by which influenza A virus nucleoprotein forms oligomers and binds RNA. Nature 2006;444:1078–1082.
247. Ng AK, Zhang H, Tan K, Li Z, Liu JH, Chan PK, Li SM, Chan WY, Au SW, Joachimiak A, Walz T, Wang JH, Shaw PC. Structure of the influenza virus A H5N1 nucleoprotein: Implications for RNA binding, oligomerization, and vaccine design. FASEB J 2008;22:3638–3647.
248. Chan WH, Ng AK, Robb NC, Lam MK, Chan PK, Au SW, Wang JH, Fodor E, Shaw PC. Functional analysis of the influenza virus H5N1 nucleoprotein tail loop reveals amino acids that are crucial for oligomerization and ribonucleoprotein activities. J Virol 2010;84:7337–7345.
249. Baudin F, Bach C, Cusack S, Ruigrok RW. Structure of influenza virus RNP. I. Influenza virus nucleoprotein melts secondary structure in panhandle RNA and exposes the bases to the solvent. EMBO J 1994;13:3158–3165.
250. Tarus B, Bertrand H, Zedda G, Di PC, Quideau S, Slama-Schwok A. Structure-based design of novel naproxen derivatives targeting monomeric nucleoprotein of influenza A virus. J Biomol Struct Dyn 2015;33:1899–1912.
251. Cheng H, Wan J, Lin MI, Liu Y, Lu X, Liu J, Xu Y, Chen J, Tu Z, Cheng YS, Ding K. Design, synthesis, and in vitro biological evaluation of 1H-1,2,3-triazole-4-carboxamide derivatives as new anti-influenza A agents targeting virus nucleoprotein. J Med Chem 2012;55:2144–2153.
252. Amorim MJ, Kao RY, Digard P. Nucleozin targets cytoplasmic trafficking of viral ribonucleoprotein-Rab11 complexes in influenza A virus infection. J Virol 2013;87:4694–4703.
253. Zarubaev VV, Beliaevskaia SV, Sirotkin AK, Anfimov PM, Nebol'sin VE, Kiselev OI, Reikhart DV. In vitro and in vivo effects of Ingavirin on the ultrastructure and infectivity of influenza virus. Vopr Virusol 2011;56:21–25.
254. Watanabe T, Kawakami E, Shoemaker JE, Lopes TJ, Matsuoka Y, Tomita Y, Kozuka-Hata H, Gorai T, Kuwahara T, Takeda E, Nagata A, Takano R, Kiso M, Yamashita M, Sakai-Tagawa Y, Katsura H, Nonaka N, Fujii H, Fujii K, Sugita Y, Noda T, Goto H, Fukuyama S, Watanabe S, Neumann G, Oyama M, Kitano H, Kawaoka Y. Influenza virus-host interactome screen as a platform for antiviral drug development. Cell Host Microbe 2014;16:795–805.
255. Ludwig S, Zell R, Schwemmle M, Herold S. Influenza, a One Health paradigm—Novel therapeutic strategies to fight a zoonotic pathogen with pandemic potential. Int J Med Microbiol 2014;304:894–901.
256. Watanabe T, Watanabe S, Kawaoka Y. Cellular networks involved in the influenza virus life cycle. Cell Host Microbe 2010;7:427–439.
257. Stertz S, Shaw ML. Uncovering the global host cell requirements for influenza virus replication via RNAi screening. Microbes Infect 2011;13:516–525.
258. Liu Q, Zhou YH, Yang ZQ. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol 2016;13:3–10.
259. Elton D, Simpson-Holley M, Archer K, Medcalf L, Hallam R, McCauley J, Digard P. Interaction of the influenza virus nucleoprotein with the cellular CRM1-mediated nuclear export pathway. J Virol 2001;75:408–419.
260. U.S. National Library of Medicine. Information on clinical trials and human research studies: Trial of safety and tolerability of oral Verdinexor (KPT-335) in healthy adults. https://clinicaltrials.gov/ct2/show/NCT02431364.
261. Naito T, Momose F, Kawaguchi A, Nagata K. Involvement of Hsp90 in assembly and nuclear import of influenza virus RNA polymerase subunits. J Virol 2007;81:1339–1349.
262. Swale C, Monod A, Tengo L, Labaronne A, Garzoni F, Bourhis JM, Cusack S, Schoehn G, Berger I, Ruigrok RW, Crepin T. Structural characterization of recombinant IAV polymerase reveals a stable complex between viral PA-PB1 heterodimer and host RanBP5. Sci Rep 2016;6:24727.
263. Pleschka S, Wolff T, Ehrhardt C, Hobom G, Planz O, Rapp UR, Ludwig S. Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade. Nat Cell Biol 2001;3:301–305.
264. Haasbach E, Reiling SJ, Ehrhardt C, Droebner K, Rückle A, Hrincius ER, Leban J, Strobl S, Vitt D, Ludwig S, Planz O. The NF-kappaB inhibitor SC75741 protects mice against highly pathogenic avian influenza A virus. Antiviral Res 2013;99:336–344.
265. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera—A visualization system for exploratory research and analysis. J Comput Chem 2004;25:1605-1612.